- Home
- BKU vs DMAC Comparison
BKU vs DMAC Comparison
Compare BKU & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- DMAC
- Stock Information
- Founded
- BKU 2009
- DMAC 2000
- Country
- BKU United States
- DMAC United States
- Employees
- BKU N/A
- DMAC N/A
- Industry
- BKU Savings Institutions
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- DMAC Health Care
- Exchange
- BKU Nasdaq
- DMAC Nasdaq
- Market Cap
- BKU 2.6B
- DMAC 178.0M
- IPO Year
- BKU 2011
- DMAC N/A
- Fundamental
- Price
- BKU $38.04
- DMAC $3.76
- Analyst Decision
- BKU Hold
- DMAC Strong Buy
- Analyst Count
- BKU 11
- DMAC 2
- Target Price
- BKU $40.27
- DMAC $8.00
- AVG Volume (30 Days)
- BKU 814.6K
- DMAC 307.4K
- Earning Date
- BKU 07-23-2025
- DMAC 08-06-2025
- Dividend Yield
- BKU 3.26%
- DMAC N/A
- EPS Growth
- BKU 38.76
- DMAC N/A
- EPS
- BKU 3.21
- DMAC N/A
- Revenue
- BKU $972,198,000.00
- DMAC N/A
- Revenue This Year
- BKU $13.53
- DMAC N/A
- Revenue Next Year
- BKU $6.80
- DMAC N/A
- P/E Ratio
- BKU $11.84
- DMAC N/A
- Revenue Growth
- BKU 11.13
- DMAC N/A
- 52 Week Low
- BKU $28.21
- DMAC $2.80
- 52 Week High
- BKU $44.45
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- BKU 72.35
- DMAC 47.18
- Support Level
- BKU $35.16
- DMAC $3.48
- Resistance Level
- BKU $35.42
- DMAC $3.99
- Average True Range (ATR)
- BKU 0.81
- DMAC 0.32
- MACD
- BKU 0.38
- DMAC -0.00
- Stochastic Oscillator
- BKU 93.64
- DMAC 41.01
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.